Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

about

Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer.

P2860

Q47207024-73C261D0-B1AC-486F-8DCC-693F7D8DA437

P2860

Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

Item

http://www.wikidata.org/entity/Q38645033

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

@en

type

Item

label

Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

@en

prefLabel

Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

@en

P1476

Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

@en

P2093

Hazel B Nichols

http://www.w3.org/2001/XMLSchema#string

Jose P Zevallos

http://www.w3.org/2001/XMLSchema#string

Mark A Weaver

http://www.w3.org/2001/XMLSchema#string

Stephanie M Engel

http://www.w3.org/2001/XMLSchema#string

P2860

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Combining information from cancer registry and medical records data to improve analyses of adjuvant cancer therapies.

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer.

Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.

A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.

The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.

Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.

P304

2291-2295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.30917

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

141

http://www.w3.org/2001/XMLSchema#string

P50

Chelsea Anderson

P577

2017-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28791691

http://www.w3.org/2001/XMLSchema#string

P932

5748086

http://www.w3.org/2001/XMLSchema#string

Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

about

P2860

P2860

Birth rates after radioactive iodine treatment for differentiated thyroid cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932